5 research outputs found
Sputum lipoarabinomannan (LAM) as a biomarker to determine sputum mycobacterial load: exploratory and model-based analyses of integrated data from four cohorts
Background
Despite the high global disease burden of tuberculosis (TB), the disease caused by Mycobacterium tuberculosis (Mtb) infection, novel treatments remain an urgent medical need. Development efforts continue to be hampered by the reliance on culture-based methods, which often take weeks to obtain due to the slow growth rate of Mtb. The availability of a “real-time” measure of treatment efficacy could accelerate TB drug development. Sputum lipoarabinomannan (LAM; an Mtb cell wall glycolipid) has promise as a pharmacodynamic biomarker of mycobacterial sputum load.
Methods
The present analysis evaluates LAM as a surrogate for Mtb burden in the sputum samples from 4 cohorts of a total of 776 participants. These include those from 2 cohorts of 558 non-TB and TB participants prior to the initiation of treatment (558 sputum samples), 1 cohort of 178Â TB patients under a 14-day bactericidal activity trial with various mono- or multi-TB drug therapies, and 1 cohort of 40Â TB patients with data from the first 56-day treatment of a standard 4-drug regimen.
Results
Regression analysis demonstrated that LAM was a predictor of colony-forming unit (CFU)/mL values obtained from the 14-day treatment cohort, with well-estimated model parameters (relative standard error ≤ 22.2%). Moreover, no changes in the relationship between LAM and CFU/mL were observed across the different treatments, suggesting that sputum LAM can be used to reasonably estimate the CFU/mL in the presence of treatment. The integrated analysis showed that sputum LAM also appears to be as good a predictor of time to Mycobacteria Growth Incubator Tube (MGIT) positivity as CFU/mL. As a binary readout, sputum LAM positivity is a strong predictor of solid media or MGIT culture positivity with an area-under-the-curve value of 0.979 and 0.976, respectively, from receiver-operator curve analysis.
Conclusions
Our results indicate that sputum LAM performs as a pharmacodynamic biomarker for rapid measurement of Mtb burden in sputum, and thereby may enable more efficient early phase clinical trial designs (e.g., adaptive designs) to compare candidate anti-TB regimens and streamline dose selection for use in pivotal trials.
Trial registration NexGen EBA study (NCT02371681
Application of cerebrospinal fluid host protein biosignatures in the diagnosis of tuberculous meningitis in children from a high burden setting
CITATION: Manyelo, C. M., et al. 2019. Application of cerebrospinal fluid host protein biosignatures in the diagnosis of tuberculous meningitis in children from a high burden setting. Mediators of Inflammation, 2019 (Article ID 7582948), doi:10.1155/2019/7582948.The original publication is available at https://www.hindawi.comPublication of this article was funded by the Stellenbosch University Open Access FundBackground. The diagnosis of tuberculous meningitis (TBM) especially in children is challenging. New tests are urgently needed for
the diagnosis of the disease, especially in resource-limited settings. Methods. We collected cerebrospinal fluid (CSF) samples from
children presenting with symptoms requiring investigation for meningitis at a tertiary hospital in Cape Town, South Africa.
Children were later classified as TBM or no TBM using published case definitions. Using a multiplex platform, we investigated
the concentrations of biomarkers comprising a previously established 3-marker biosignature (VEGF, IL-13, and LL-37) and
other potentially useful host biomarkers as diagnostic candidates for TBM. Findings. Out of 47 children, age, 3 months to
13 years, 23 were diagnosed with TBM and six (16%) were HIV-infected. We validated the previously identified CSF
biosignature (sensitivity of 95.7% (95% CI, 79.0-99.2%) and specificity of 37.5% (95% CI, 21.2-57.3%)). However, substitution of
IL-13 and LL-37 with IFN-Îł and MPO, respectively, resulted in improved accuracy (area under the ROC curve (AUC) = 0 97,
95% CI, 0.92-1.00, up to 91.3% (21/23) sensitivity and up to 100% (24/24) specificity). An alternative four-marker biosignature
(sICAM-1, MPO, CXCL8, and IFN-Îł) also showed potential, with an AUC of 0.97. Conclusion. We validated a previously
identified CSF biosignature and showed that refinement of this biosignature by incorporation of other biomarkers diagnosed
TBM with high accuracy. Incorporation of these biomarkers into a point-of-care or bedside diagnostic test platform may result
in the improved management of TBM in children.https://www.hindawi.com/journals/mi/2019/7582948/Publisher's versio
Detection of a combination of serum IgG and IgA antibodies against selected mycobacterial targets provides promising diagnostic signatures for active TB
CITATION: Awoniyi, D. O., et al. 2017. Detection of a combination of serum IgG and IgA antibodies against selected mycobacterial targets provides promising diagnostic signatures for active TB. Oncotarget, 8(23):37525-37537, doi:10.18632/oncotarget.16401.The original publication is available at http://www.oncotarget.comENGLISH ABSTRACT: Immunoglobulin G (IgG) based tests for the diagnosis of active tuberculosis (TB)
disease often show a lack of specificity in TB endemic regions, which is mainly due to a
high background prevalence of LTBI. Here, we investigated the combined performance
of the responses of different Ig classes to selected mycobacterial antigens in primary
healthcare clinic attendees with signs and symptoms suggestive of TB. The sensitivity
and specificity of IgA, IgG and/or IgM to LAM and 7 mycobacterial protein antigens
(ESAT-6, Tpx, PstS1, AlaDH, MPT64, 16kDa and 19kDa) and 2 antigen combinations
(TUB, TB-LTBI) in the plasma of 63 individuals who underwent diagnostic work-up
for TB after presenting with symptoms and signs compatible with possible active
TB were evaluated. Active TB was excluded in 42 individuals of whom 21 has LTBI
whereas active TB was confirmed in 21 patients of whom 19 had a follow-up blood
draw at the end of 6-month anti-TB treatment. The leading single serodiagnostic
markers to differentiate between the presence or absence of active TB were anti-16
kDa IgA, anti-MPT64 IgA with sensitivity and specificity of 90%/90% and 95%/90%,
respectively. The combined use of 3 or 4 antibodies further improved this performance
to accuracies above 95%. After successful completion of anti-TB treatment at month
6, the levels of 16 kDa IgA and 16 kDa IgM dropped significantly whereas LAM IgG and
TB-LTBI IgG increased. These results show the potential of extending investigation
of anti-tuberculous IgG responses to include IgM and IgA responses against selected
protein and non-protein antigens in differentiating active TB from other respiratory
diseases in TB endemic settings.http://www.oncotarget.com/index.php?journal=oncotarget&page=article&op=view&path[]=16401&path[]=52484Publisher's versio
Africa-wide evaluation of host biomarkers in QuantiFERON supernatants for the diagnosis of pulmonary tuberculosis
Abstract We investigated host-derived biomarkers that were previously identified in QuantiFERON supernatants, in a large pan-African study. We recruited individuals presenting with symptoms of pulmonary TB at seven peripheral healthcare facilities in six African countries, prior to assessment for TB disease. We then evaluated the concentrations of 12 biomarkers in stored QuantiFERON supernatants using the Luminex platform. Based on laboratory, clinical and radiological findings and a pre-established algorithm, participants were classified as TB disease or other respiratory diseases(ORD). Of the 514 individuals included in the study, 179(34.8%) had TB disease, 274(51.5%) had ORD and 61(11.5%) had an uncertain diagnosis. A biosignature comprising unstimulated IFN-γ, MIP-1β, TGF-α and antigen-specific levels of TGF-α and VEGF, identified on a training sample set (n = 311), validated by diagnosing TB disease in the test set (n = 134) with an AUC of 0.81(95% CI, 0.76–0.86), corresponding to a sensitivity of 64.2%(95% CI, 49.7–76.5%) and specificity of 82.7%(95% CI, 72.4–89.9%). Host biomarkers detected in QuantiFERON supernatants can contribute to the diagnosis of active TB disease amongst people presenting with symptoms requiring investigation for TB disease, regardless of HIV status or ethnicity in Africa
Evaluation of cytokine responses against novel Mtb antigens as diagnostic markers for TB disease
Objective:
We investigated the accuracy of host markers detected in Mtb antigen-stimulated whole blood culture supernatant in the diagnosis of TB.
Methods:
Prospectively, blood from 322 individuals with presumed TB disease from six African sites was stimulated with four different Mtb antigens (Rv0081, Rv1284, ESAT-6/CFP-10, and Rv2034) in a 24 h whole blood stimulation assay (WBA). The concentrations of 42 host markers in the supernatants were measured using the Luminex multiplex platform. Diagnostic biosignatures were investigated through the use of multivariate analysis techniques.
Results:
17% of the participants were HIV infected, 106 had active TB disease and in 216 TB was excluded. Unstimulated concentrations of CRP, SAA, ferritin and IP-10 had better discriminating ability than markers from stimulated samples. Accuracy of marker combinations by general discriminant analysis (GDA) identified a six analyte model with 77% accuracy for TB cases and 84% for non TB cases, with a better performance in HIV uninfected patients.
Conclusions:
A biosignature of 6 cytokines obtained after stimulation with four Mtb antigens has moderate potential as a diagnostic tool for pulmonary TB disease individuals and stimulated marker expression had no added value to unstimulated marker performance